Meridian Pharmaceuticals
At risk35/100LargePharmaceutical
About this account
Global generics + specialty; high-volume ANDA/MAA submissions.
Relationship health
35/100 · At riskHow this account's health has moved over the last 5 weeks.
100 pts0 pts
4w ago2w agothis week
How touches have landed
Every logged touch with Meridian Pharmaceuticals, by outcome.
Not Interested1100%
Company profile
Not analyzed yet — analyze to qualify its type, ownership and revenue from the web, and the offerings that fit show automatically.
Agent briefing
Meridian Pharmaceuticals needs attention — at risk, with $815K in open pipeline at stake. It's single-threaded, so widening the relationship would de-risk the deal. Recommended next move: Stabilize Meridian Pharmaceuticals.
HealthAt risk (35/100).
Pipeline1 open deal worth $815K.
ThreadingSingle-threaded on Claudia Hofmann — widen the relationship to de-risk.
MomentumLast touch Jul 4, 2026 • 2:28 PM.
Recommended: Stabilize Meridian Pharmaceuticals
Key Contacts
Global Head, Reg Submissions
Value PropositionsAI generated
Regulatory Submission Services90% match
Position Regulatory Submission Services against Meridian Pharmaceuticals's near-term regulatory milestones.
Matched from your Freyr knowledge base
Regulatory Intelligence70% match
Single-pane monitoring across FDA, EMA and 120+ agencies.
Matched from your Freyr knowledge base
Angles to researchAI generated
Agent-suggested things worth checking before you reach out — verify before you rely on them.
Regulatory
Check for recent Pharmaceutical guidance that could tighten their submission timelines — a timely reason to reach out.
Hiring
See whether Meridian is hiring in regulatory affairs — a growing team often means more submission workload they may need help with.